--
Victoria
1: Norlock FE. Related Articles
Benign breast pain in women: a practical approach to evaluation and treatment.
J Am Med Womens Assoc. 2002 Spring;57(2):85-90. Review.
PMID: 11991427 [PubMed - indexed for MEDLINE]
2: Horner NK, Lampe JW. Related Articles
Potential mechanisms of diet therapy for fibrocystic breast conditions show inadequate evidence of effectiveness.
J Am Diet Assoc. 2000 Nov;100(11):1368-80. Review.
PMID: 11103660 [PubMed - indexed for MEDLINE]
3: Gateley CA, Maddox PR, Pritchard GA, Sheridan W, Harrison BJ, Pye JK, Webster DJ, Hughes LE, Mansel RE. Related Articles
Plasma fatty acid profiles in benign breast disorders.
Br J Surg. 1992 May;79(5):407-9.
PMID: 1596720 [PubMed - indexed for MEDLINE]
4: Mansel RE, Harrison BJ, Melhuish J, Sheridan W, Pye JK, Pritchard G, Maddox PR, Webster DJ, Hughes LE. Related Articles
A randomized trial of dietary intervention with essential fatty acids in patients with categorized cysts.
Ann N Y Acad Sci. 1990;586:288-94.
PMID: 2192634 [PubMed - indexed for MEDLINE]
5: Maddox PR, Mansel RE. Related Articles
Management of breast pain and nodularity.
World J Surg. 1989 Nov-Dec;13(6):699-705. Review.
PMID: 2696222 [PubMed - indexed for MEDLINE]
Some investigations did find associations between breast pain and premenstrual syndrome, fibrocystic breast disease, and caffeine intake. Initial treatment with reassurance, a well-fitted brassiere, caffeine reduction, and primrose oil should be tried before prescribing pharmaceutical agents. Medications such as danazol, bromocriptine, and tamoxifen are effective, but often have side effects and contraindications. Future studies should indude double-blind, randomized, controlled trials of selective-serotonin reuptake inhibitors and primrose oil and single-blind, randomized, controlled trials advising caffeine reduction.
We reviewed the literature to evaluate evidence supporting nutrition interventions commonly recommended for fibrocystic breast conditions by health care providers. Randomized, controlled studies of the effectiveness of caffeine restriction fail to support any benefit in fibrocystic breast conditions. Similarly, evidence supporting evening primrose oil, vitamin E, or pyridoxine as treatments for the discomforts of fibrocystic breast conditions is insufficient to draw conclusions about effectiveness. Dietary alterations that influence the intermediate markers for fibrocystic breast conditions include low-fat (15% to 20% energy), high-fiber (30 g/day), and soy isoflavone regimens. However, our findings provide no solid evidence for secondary prevention or treatment of fibrocystic breast conditions through a dietary approach. Health care providers should limit recommendations to proven diet therapies supported by randomized, placebo-controlled trials, given the instability inherent in fibrocystic breast conditions and the near 20% placebo effect associated with intervention. Because excessive estrogen or altered sensitivity to estrogen is the dominant theory of etiology, interventions that may modulate endogenous steroid hormones warrant further investigation as potential treatments for symptomatic fibrocystic breast conditions.
Breast pain (mastalgia) and macroscopic breast cysts present commonly. Mastalgia may be improved by dietary manipulation to reduce saturated fat or supplement essential fatty acid intake. Fatty acid profiles were measured in women with mastalgia and breast cysts, before and during treatment with evening primrose oil, a rich source of essential fatty acids. The fatty acid profiles of both groups of patients were abnormal, with increased proportions of saturated fatty acids and reduced proportions of essential fatty acids. Treatment with evening primrose oil improved the fatty acid profiles towards normal, but this was not necessarily associated with a clinical response.
Recurrent cyst formation in the first year was slightly (but not significantly) lower in the Efamol group compared with the placebo-treated group. The Efamol treatment was well tolerated as the dropout rate was only 7% and equal in both the active and placebo groups. The initial electrolyte composition did not predict for cyst recurrence.
Only a small number of drugs have been adequately tested in controlled trails and have been demonstrated to be more effective than placebo; these are bromocriptine, danazol, evening primrose oil, and tamoxifen. No ideal agent exists and the choice of drug will depend on efficacy, side effects, and cost.
![[ PCOS Discussion Forums ]](../../images/pcos_at_obgyn.gif)